
UMC · NYSE
Consensus is Underperform across all six analysts. The supplied data disclose only a mean price target of $10.05; low and high targets are unavailable, so there is no support for identifying a target cluster or measuring the spread. No named analyst or firm is provided, preventing identification of the most or least bullish view. The evidence also contains no rating or target revisions during the week. The substantive disagreement is between improving operating indicators—an earnings beat, 8.4% revenue growth, expanding margins, record 22-nanometer sales and AI-related investment—and the prevailing valuation view, which leaves every tracked analyst at Underperform and places the disclosed mean target far below the stock's reported close.